Treatment Outcomes of the Drug Resistant Tuberculosis Cases Previously Exposed to Second Line Anti Tuberculosis Drugs in Pakistan: a Multi-center Cross-sectional Study. | [Journal of Pakistan Medical Association • 2019]

Author(s):

1. Rabab Batool: Agha Khan University Hospital, Karachi, Pakistan

2. Sher Wali Khan: Indus Hospital Research Center, Karachi, Pakistan

3. Mohammad Imran: College of Medical Technology, Ziauddin University, Karachi, Pakistan

4. Zainab Barry: The Indus Hospital, Karachi, Pakistan

5. Shaikh Zafar Ali: King Fahad Hospital,

Abstract:

Objectives: To determine the treatment outcomes of the drug-resistant tuberculosis patients who were previously exposed to second line drugs. Methods: The retrospective study was conducted at eight Programmatic Management of Drug Resistant Tuberculosis (PMDT) sites in Sindh and Balochistan. Data of patients who were previously exposed to second line drugs and re-enrolled in the drug-resistant tuberculosis register at PMDT sites in Sindh and Balochistan between 2008 and 2016 was included for analysis. Data of those still under treatment or transferred to another treatment site was excluded. Association was explored between treatment outcomes and other independent variables, while in order to identify the risk factors associated with poor treatment outcomes univariate and multivariate logistic regression was used. Results: Overall, there were 3645 patients and 288(8%) were previously exposed to second line drugs. Of them, 95(33%) were excluded, and the final sample stood at 193; 99(51.3%) males and 94(48.7%) females. The median age of the sample was 29 years (inter-quartile range: 22-41 years). The mean duration of treatment was 20±11.14 months. Overall success rate of the re-treatment of previously treated patients was 105(54.4%). Observed relapse rate was 9(4.7%). Conclusion: The success rate for re-treatment drug-resistant tuberculosis patients was found to be unacceptably low. New drugs and novel regimens should be made widely available.

Page(s): 4-10

DOI: DOI not available

Published: Journal: Journal of Pakistan Medical Association, Volume: 69, Issue: 1, Year: 2019

Keywords:

Sophisticated , Second line

References:

[1] OrmerodLP, 2005.Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment,Br Med Bull 73 17 -24

[2] BecerraMC,AppletonSC,FrankeMF,ChalcoK,BayonaJ,MurrayMB, 2010.Recurrence after treatment for pulmonary multidrugresistant tuberculosis,Clin Infect Dis 51 709 -11

[3] LeeJ,LimH,ChoY,ParkY,LeeS,YangS, 2011.Recurrence after successful treatment among patients with multidrug-resistant tuberculosis,Int J Tuberc Lung Dis 15 1331 -3

[4] EnnassiriW,JaouhariS,CherkiW,CharofR,Filali-MaltoufA,LahlouO, 2017.Extensively drug-resistant tuberculosis (XDR-TB) in Morocco,J Glob Antimicrob Resist 11 75 -80

[5] MukherjeeJS,RichML,SocciAR,JosephJK,VirúFA,ShinSS, 2004.Programmes and principles in treatment of multidrug-resistant tuberculosis,Lancet 363 474 -81

[6] JohnstonJC,ShahidiNC,SadatsafaviM,FitzgeraldJM, 2009.Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis,PloS one 4 e6914 -

[7] LangeC,AbubakarI,AlffenaarJW,BothamleyG,CamineroJA,CarvalhoACC, 2014.Management of patients with multidrugresistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement,Eur Respir J 44 23 -63

[8] MorrisMD,QuezadaL,BhatP,MoserK,SmithJ,PerezH, 2013.Social, economic, and psychological impacts of MDR-TB treatment in Tijuana, Mexico: a patient's perspective,Int J Tuberc Lung Dis 17 954 -60

[9] BrodeSK,VaradiR,McNameeJ,MalekN,StewartS,JamiesonFB, 2015.Multidrug-resistant tuberculosis: treatment and outcomes of 93 patients,Can Respir J 22 97 -102

[10] KhanMA,MehreenS,BasitA,KhanRA,JanF,UllahI, 2015.Characteristics and treatment outcomes of patients with multidrug resistant tuberculosis at a tertiary care hospital in Peshawar, Pakistan,Saudi Med J 36 1463 -71

[11] YangTW,ParkHO,JangHN,YangJH,KimSH,MoonSH, 2017.Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: A retrospective study,Medicine (Baltimore) 96 e7482 -

[12] TörünT,GüngörG,ÖzmenI,BölükbaşıY,MadenE,BıçakçıB, ., -

[13] 2005.Side effects associated with the treatment of multidrug-resistant tuberculosis,Int J Tuberc Lung Dis 9 1373 -7

[14] Chung-DelgadoK,Guillen-BravoS,Revilla-MontagA,BernabeOrtizA, 2015.Mortality among MDR-TB cases: comparison with drugsusceptible tuberculosis and associated factors,PloS one 10 e0119332 -

[15] 2016.,Biomed Environ Sci 29 91 -8

[16] DeanA,Soe M. OpenEpi, 2011.,Version 23 -

[17] ChenMY,LoYC,ChenWC,WangKF,ChanPC, 2017.Recurrence after Successful Treatment of Multidrug-Resistant Tuberculosis in Taiwan,PloS one 12 e0170980 -

[18] QadeerE,FatimaR,FieldingK,QaziF,MooreD,KhanMS, 2015.Good quality locally procured drugs can be as effective as internationally quality assured drugs in treating multi-drug resistant tuberculosis,PloS one 10 e0126099 -

[19] 2016.Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis (MDR-TB) Compared with Non-MDR-TB Infections in Peninsular Malaysia,Malays J Med Sci 23 17 -25

[20] 2000.Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens,Chest 117 744 -51

[21] MibeiD,KiarieJ,WairiaA,KameneM,OkumuM., 2016.Treatment outcomes of drug-resistant tuberculosis patients in Kenya,Int J Tuberc Lung Dis 20 1477 -82

[22] NairD,VelayuthamB,KannanT,TripathyJ,HarriesA,NatrajanM, 2017.Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India,Public Health Action 7 32 -8

[23] JanmejaA,AggarwalD,DhillonR, 2017.Analysis of treatment outcome in multi-drug resistant tuberculosis patients treated under programmatic conditions,Int J Res Med Sci 5 2401 -5

Citations

Downloads

Views